Jon Kaiser

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search
Jon Kaiser.png

Jon D. Kaiser, MD, is a Clinical Associate at the University of California at San Francisco School of Medicine[1], a past board member of International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[2], previous Medical Director of K-PAX Pharmaceuticals[3], and a physician in private practice specializing in integrative medicine and the treatment of people with diseases of the nervous and immune systems.

Dr. Kaiser personally suffered from ME/CFS for over fifteen years. "It took me five years to recover to the point where I was close to normally functional. If I worked too hard, if some sort of stress occurred that I couldn't avoid, I would have a relapse lasting days to weeks," Kaiser said. "One of the things that got me interested in micronutrients and supplements early on was using them to help support my recovery."[3] I also developed several mind-body techniques that we're extremely helpful in my recovery from ME/CFS.

As Medical Director of K-PAX Pharmaceuticals, Dr. Kaiser helped perform the Synergy Trial, a double-blind, placebo-controlled clinical trial of a new treatment designed to improve the fatigue and decreased concentration symptoms in people with Chronic Fatigue Syndrome (CFS). The treatment combines a low dosage of a prescription stimulant medication, methylphenidate hydrochloride, with broad-spectrum mitochondrial support nutrients.[4]

At the beginning of 2020, Dr. Kaiser returned to private medical practice in Mill Valley, California and currently consults with patients worldwide using telemedicine. In 2019, Dr. Kaiser wrote an E-book titled "A Healing Program for Fibro & Fatigue" that can be obtained free on his medical practice website.

Education

  • Bachelor of Science degrees in biochemistry and philosophy from the State University of New York at Binghamton.
  • MD, from University of Texas Medical School in Houston, receiving honors in Internal Medicine and Emergency Medicine.[5]

Articles[edit | edit source]

Talks and interviews[edit | edit source]

Notable studies[edit | edit source]

  • 2015, A prospective, proof-of-concept investigation of KPAX002 in chronic fatigue syndrome.[7](Full Text)
  • 2018, KPAX002 as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A prospective, randomized trial[8](Full Text)

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. USCF directory page for Jon D. Kaiser 
  2. IACFS/ME homepage 
  3. 3.03.1 Halstead, Richard (Mar 22, 2014), "Mill Valley company develops treatment for mysterious chronic fatigue syndrome.", Marin Independent Journal. 
  4. Jon D. Kaiser homepage 
  5. Biography, Jon D. Kaiser 
  6. Kaiser, J; Gustafson, C (July 2015), "Supporting Mitochondrial Health With Nutrient Therapy.", Alternative Therapies in Health and Medicine, 21 (Suppl 2): 77-79, PMID 26308764 
  7. Kaiser, JD (Jul 15, 2015), "A prospective, proof-of-concept investigation of KPAX002 in chronic fatigue syndrome", International Journal of Clinical and Experimental Medicine, 8 (7): 11064–11074, PMID 26379906 
  8. Montoya, Jose G; Anderson, Jill N; Adolphs, Danya L; Bateman, Lucinda; Klimas, Nancy; Levine, Susan M; Garvert, Donn W; Kaiser, Jon D (2018), "KPAX002 as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A prospective, randomized trial" (PDF), International Journal of Clinical and Experimental Medicine, 11 (3): 2890-2900 

ME/CFS - An acronym that combines myalgic encephalomyelitis with chronic fatigue syndrome. Sometimes they are combined because people have trouble distinguishing one from the other. Sometimes they are combined because people see them as synonyms of each other.

double blinded trial - A clinical trial is double blinded if neither the participants nor the researchers know which treatment group they are allocated to until after the results are interpreted. This reduces bias. (Learn more: www.nottingham.ac.uk)

chronic fatigue syndrome (CFS) - A fatigue-based illness. The term CFS was invented invented by the U.S. Centers for Disease Control as an replacement for myalgic encephalomyelitis (ME). Some view CFS as a neurological disease, others use the term for any unexplained long-term fatigue. Sometimes used as a the term as a synonym of myalgic encephalomyelitis, despite the different diagnostic criteria.

mitochondria - Important parts of the biological cell, with each mitochondrion encased within a mitochondrial membrane. Mitochondria are best known for their role in energy production, earning them the nickname "the powerhouse of the cell". Mitochondria also participate in the detection of threats and the response to these threats. One of the responses to threats orchestrated by mitochondria is apoptosis, a cell suicide program used by cells when the threat can not be eliminated.

mitochondria - Important parts of the biological cell, with each mitochondrion encased within a mitochondrial membrane. Mitochondria are best known for their role in energy production, earning them the nickname "the powerhouse of the cell". Mitochondria also participate in the detection of threats and the response to these threats. One of the responses to threats orchestrated by mitochondria is apoptosis, a cell suicide program used by cells when the threat can not be eliminated.

chronic fatigue syndrome (CFS) - A fatigue-based illness. The term CFS was invented invented by the U.S. Centers for Disease Control as an replacement for myalgic encephalomyelitis (ME). Some view CFS as a neurological disease, others use the term for any unexplained long-term fatigue. Sometimes used as a the term as a synonym of myalgic encephalomyelitis, despite the different diagnostic criteria.

myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.